Han Lin

Han Lin

Auto-generated profile, based on publicly available information

Han Lin

Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
YSYanqi Shen
Yanqi Shen
JGJiatong Gu
Jiatong Gu
LZLulu Zhu
Lulu Zhu
XMXun Mingjuan
Xun Mingjuan
BPBo Pang
Bo Pang
JYJun Yan
Jun Yan
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAM), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1–AMFR axis as a critical contributor to GBM progression through dual immunomodulatory and tumor-intrinsic mechanisms. Analysis of human glioma datasets and tissue samples revealed that CCL1—predominantly derived from TAMs—was significantly overexpressed in GBM and correlated with poor patient survival. Functionally, CCL1 recruited Arg1+ immunosuppressive macrophages in an AMFR-dependent manner. Myeloid-specific knockout of either Ccl1 or Amfr in murine models reduced TAM infiltration and extended survival. Although CCL1 can signal through both CCR8 and its recently identified receptor AMFR, AMFR played the dominant role in mediating CCL1-induced tumor cell proliferation and migration by activating the FAK and PI3K–AKT signaling pathways. Importantly, therapeutic neutralization of CCL1 using a monoclonal antibody significantly prolonged median survival in both immunocompetent GL261 murine GBM and BNI1-3 patient-derived xenograft models, accompanied by reduced TAM infiltration and attenuated FAK/PI3K–AKT signaling. Our findings establish TAM-derived CCL1 as a pivotal regulator of GBM pathogenesis and demonstrate that targeting the CCL1–AMFR axis disrupts both tumor-intrinsic growth and immunosuppressive TME dynamics, representing a promising therapeutic strategy for this lethal malignancy.

28 September 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
HYHao Yan
Hao Yan
JJJialin Jin
Jialin Jin
YCYuzhou Chang
Yuzhou Chang
BPBo Pang
Bo Pang
HLHan Lin
Han Lin
YWYongzhi Wang
Yongzhi Wang
Background: H3 K27-altered diffuse midline gliomas (H3-DMGs) are driven by stem-like and proliferative tumor cells resulting from global H3K27me3 loss. Here, we aimed to identify key molecular mechanisms involved in the interplay between epigenetic and epitranscriptomic regulation underlying this process. Methods: Patient-derived spinal cord H3-DMG stem-like spheres and serum-induced differentiated cells were used to model tumor plasticity. Multi-omics approaches, including single-cell RNA sequencing, spatial transcriptomics, RNA m6A profiling, CUT&Tag, ATAC-seq, and in vitro and in vivo assays were performed to dissect epigenetic and epitranscriptomic regulation of stemness. Results: Differentiation reduced stemness markers, proliferation, H3K27M expression, and global m6A levels, while increasing H3K27me3. METTL3 was significantly downregulated during differentiation and positively correlated with stemness and proliferation in patient tumors. METTL3 promoted tumor stemness and growth by stabilizing SOX11 mRNA through YTHDC2-dependent m6A recognition. In parallel, H3K27me3 loss relieved transcriptional repression at both METTL3 and SOX11 loci, leading to SOX11 overexpression. Functionally, SOX11 interacted with SMARCA4, the core ATPase of the SWI/SNF complex, to enhance chromatin accessibility and activate stemness-associated transcriptional programs marked by H3K27ac and H3K4me3 enrichment. Clinically, METTL3 and SOX11 were upregulated in H3K27M-mutant tumors, and high SOX11 expression correlated with increased proliferation, poor prognosis, and enhanced sensitivity to the SMARCA4 inhibitor BRM014. Conclusions: H3K27M-driven epigenetic dysregulation promotes SOX11 overexpression through combined H3K27me3 loss and METTL3-mediated m6A modification. SOX11 sustains tumor stemness and proliferation by recruiting SMARCA4 to remodel chromatin and serves as both a prognostic biomarker and a predictor of response to SMARCA4-targeted therapy in spinal cord H3-DMG.

2 April 2026
Verified
Other
Open access
YSYanqi Shen
Yanqi Shen
JGJiatong Gu
Jiatong Gu
LZLulu Zhu
Lulu Zhu
XMXun Mingjuan
Xun Mingjuan
BPBo Pang
Bo Pang
JYJun Yan
Jun Yan
Figure S4. Expression profiles of CCL1, CCR8 and AMFR in GBM.

2 April 2026
Verified
Other
Open access
YSYanqi Shen
Yanqi Shen
JGJiatong Gu
Jiatong Gu
LZLulu Zhu
Lulu Zhu
XMXun Mingjuan
Xun Mingjuan
BPBo Pang
Bo Pang
JYJun Yan
Jun Yan
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAM), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1–AMFR axis as a critical contributor to GBM progression through dual immunomodulatory and tumor-intrinsic mechanisms. Analysis of human glioma datasets and tissue samples revealed that CCL1—predominantly derived from TAMs—was significantly overexpressed in GBM and correlated with poor patient survival. Functionally, CCL1 recruited Arg1+ immunosuppressive macrophages in an AMFR-dependent manner. Myeloid-specific knockout of either Ccl1 or Amfr in murine models reduced TAM infiltration and extended survival. Although CCL1 can signal through both CCR8 and its recently identified receptor AMFR, AMFR played the dominant role in mediating CCL1-induced tumor cell proliferation and migration by activating the FAK and PI3K–AKT signaling pathways. Importantly, therapeutic neutralization of CCL1 using a monoclonal antibody significantly prolonged median survival in both immunocompetent GL261 murine GBM and BNI1-3 patient-derived xenograft models, accompanied by reduced TAM infiltration and attenuated FAK/PI3K–AKT signaling. Our findings establish TAM-derived CCL1 as a pivotal regulator of GBM pathogenesis and demonstrate that targeting the CCL1–AMFR axis disrupts both tumor-intrinsic growth and immunosuppressive TME dynamics, representing a promising therapeutic strategy for this lethal malignancy.


2 April 2026
Verified
Other
Open access
YSYanqi Shen
Yanqi Shen
JGJiatong Gu
Jiatong Gu
LZLulu Zhu
Lulu Zhu
XMXun Mingjuan
Xun Mingjuan
BPBo Pang
Bo Pang
JYJun Yan
Jun Yan
Figure S1. Schematic of the Cre-LoxP-Mediated Gene Targeting to Generate gene-specific knockout mice.